TY - JOUR
T1 - VitalSign 6
T2 - Screening, Diagnosis, and Treatment of Depression for Adolescents Presenting to Pediatric Primary and Specialty Care Settings
AU - Pop, Radu
AU - Kinney, Robert
AU - Grannemann, Bruce
AU - Emslie, Graham
AU - Trivedi, Madhukar H.
N1 - Funding Information:
Disclosure: Dr. Emslie has received research funding from Duke University and Forest Laboratories. He has served as a consultant for Alkermes, Allergan, Assurex Health, Inc., Bristol Myers Squibb Company, INC. Research Inc., Lundbeck, NCS Pearson, Neuronetics, Otsuka, Pfizer Inc., and the Texas Department of State Health Services. Dr. Trivedi has received consulting or advisory board fees from AcademyHealth, ACADIA Pharmaceuticals, Akili Interactive, Alkermes Inc., Allergan, Axsome Therapeutics, Boehringer Ingelheim, Janssen Pharmaceutical, Jazz Pharmaceutical, Lundbeck Research USA, Medscape, Navitor, One Carbon Therapeutics, Otsuka America Pharmaceutical Inc., Oxford Pharmagenesis, and SAGE Therapeutics. He has received research funding from the National Institute of Mental Health, the National Institute on Drug Abuse, the Patient-Centered Outcomes Research Institute (PCORI), the Cancer Prevention Research Institute of Texas (CPRIT), Johnson and Johnson, and Janssen Research and Development, LLC. He has received editorial compensation from Healthcare Global Village, Engage Health Media, and Oxford University Press. Drs. Pop and Kinney and Mr. Grannemann report no biomedical financial interests or potential conflicts of interest. Disclosure: Dr. Emslie has received research funding from Duke University and Forest Laboratories. He has served as a consultant for Alkermes, Allergan, Assurex Health, Inc., Bristol Myers Squibb Company, INC. Research Inc., Lundbeck, NCS Pearson, Neuronetics, Otsuka, Pfizer Inc., and the Texas Department of State Health Services. Dr. Trivedi has received consulting or advisory board fees from AcademyHealth, ACADIA Pharmaceuticals, Akili Interactive, Alkermes Inc., Allergan, Axsome Therapeutics, Boehringer Ingelheim, Janssen Pharmaceutical, Jazz Pharmaceutical, Lundbeck Research USA, Medscape, Navitor, One Carbon Therapeutics, Otsuka America Pharmaceutical Inc., Oxford Pharmagenesis, and SAGE Therapeutics. He has received research funding from the National Institute of Mental Health, the National Institute on Drug Abuse, the Patient-Centered Outcomes Research Institute (PCORI), the Cancer Prevention Research Institute of Texas (CPRIT), Johnson and Johnson, and Janssen Research and Development, LLC. He has received editorial compensation from Healthcare Global Village, Engage Health Media, and Oxford University Press. Drs. Pop and Kinney and Mr. Grannemann report no biomedical financial interests or potential conflicts of interest.
Publisher Copyright:
© 2019
PY - 2019/6
Y1 - 2019/6
N2 - Depression in youth is a critical public health concern. Nearly 13% of adolescents have experienced a depressive episode within the last year,1 and suicide is the second leading cause of death among 15- to 24-year-olds.2 Depression's negative impact spans several domains of functioning, leading to long-term effects on development.3 Recognizing the magnitude of the crisis, renewed guidelines by the US Preventive Services Taskforce and the American Academy of Pediatrics suggest that pediatric primary care providers become more active in the screening, diagnosis, and treatment of depression.4,5 Primary care settings provide optimal opportunities to identify and treat depression, while reducing stigma and barriers surrounding mental health, particularly given the limited availability and cost of psychiatric specialists. Although providers cite difficulties, including insufficient appointment time, inadequate training, discomfort addressing mental health disorders, and stigma, the management of depressed patients is feasible and efficacious in primary care.6-8 Several cost-efficient and easy-to-use depression screening tools are readily available and can be used alongside clinical interviews to diagnose and initiate treatment. In the following letter, we examine the feasibility of implementing a program focused on supporting pediatric providers in screening, diagnosing, and initiating depression treatment in youth.
AB - Depression in youth is a critical public health concern. Nearly 13% of adolescents have experienced a depressive episode within the last year,1 and suicide is the second leading cause of death among 15- to 24-year-olds.2 Depression's negative impact spans several domains of functioning, leading to long-term effects on development.3 Recognizing the magnitude of the crisis, renewed guidelines by the US Preventive Services Taskforce and the American Academy of Pediatrics suggest that pediatric primary care providers become more active in the screening, diagnosis, and treatment of depression.4,5 Primary care settings provide optimal opportunities to identify and treat depression, while reducing stigma and barriers surrounding mental health, particularly given the limited availability and cost of psychiatric specialists. Although providers cite difficulties, including insufficient appointment time, inadequate training, discomfort addressing mental health disorders, and stigma, the management of depressed patients is feasible and efficacious in primary care.6-8 Several cost-efficient and easy-to-use depression screening tools are readily available and can be used alongside clinical interviews to diagnose and initiate treatment. In the following letter, we examine the feasibility of implementing a program focused on supporting pediatric providers in screening, diagnosing, and initiating depression treatment in youth.
UR - http://www.scopus.com/inward/record.url?scp=85066024005&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066024005&partnerID=8YFLogxK
U2 - 10.1016/j.jaac.2019.01.019
DO - 10.1016/j.jaac.2019.01.019
M3 - Letter
C2 - 30953732
AN - SCOPUS:85066024005
SN - 0890-8567
VL - 58
SP - 632
EP - 635
JO - Journal of the American Academy of Child Psychiatry
JF - Journal of the American Academy of Child Psychiatry
IS - 6
ER -